AQP9 and metabolic dysfunction-associated steatotic liver disease: The downregulation of AQP9 seems to be a compensatory mechanism whereby the liver counteracts further TG accumulation within its parenchyma as well as reduces hepatic gluconeogenesis in obese patients with NAFLD.